These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 22945774)

  • 1. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
    Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
    Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
    Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
    van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
    Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia.
    Hrabovsky S; Folber F; Horacek JM; Stehlikova O; Jelinkova H; Salek C; Doubek M;
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):743-748. PubMed ID: 30057330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
    Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
    Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of minimal residual disease in acute leukemia.
    van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
    J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
    Szczepański T
    Leukemia; 2007 Apr; 21(4):622-6. PubMed ID: 17301806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
    Brüggemann M; Gökbuget N; Kneba M
    Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
    van der Velden VH; van Dongen JJ
    Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.